STEAP1: A Protein Targeted for Drug Development (G26872)

Target Name: STEAP1

NCBI ID: G26872

STEAP1

STEAP1: A Protein Targeted for Drug Development

STEAP1 (MGC19484) is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and muscle. It is a member of the Steen family of proteins, which are involved in the regulation of cell signaling pathways.

Recent studies have identified STEAP1 as a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its function in these diseases has been studied extensively, and its potential as a drug target has led to a number of research studies and clinical trials.

One of the key reasons for the interest in STEAP1 as a drug target is its role in the regulation of cell signaling pathways. STEAP1 has been shown to play a role in the regulation of several key signaling pathways, including the TGF-β pathway, the PI3K/Akt pathway, and the NF-kappa-B pathway. These pathways are involved in the regulation of cell growth, differentiation, and survival, and are often disrupted in diseases such as cancer, neurodegenerative diseases, and autoimmune disorders.

In addition to its role in cell signaling pathways, STEAP1 has also been shown to play a role in the regulation of inflammation. Studies have shown that STEAP1 is involved in the regulation of the production and function of immune cells, including T cells and macrophages. This suggests that STEAP1 may be a useful target for drugs that are aimed at reducing inflammation and improving immune function in diseases such as cancer and autoimmune disorders.

Another potential reason for the interest in STEAP1 as a drug target is its role in the regulation of cell metabolism and energy homeostasis. STEAP1 has been shown to play a role in the regulation of glucose metabolism and lipid metabolism, which are important for maintaining cellular energy homeostasis. Disruptions in these processes have been implicated in a number of diseases, including obesity, type 2 diabetes, and certain cancers.

In addition to its role in cell signaling pathways, STEAP1 has also been shown to play a role in the regulation of cellular processes that are important for maintaining tissue structure and homeostasis. Studies have shown that STEAP1 is involved in the regulation of cell migration, invasion, and adhesion, as well as in the regulation of cell-cell and cell-tissue interactions. These processes are important for maintaining the structure and function of tissues, and are often disrupted in diseases such as cancer and neurodegenerative diseases.

Given the potential role of STEAP1 in several diseases, there is significant interest in developing drugs that can target this protein. Several research studies have been conducted to investigate the potential of drugs that can inhibit STEAP1 function, with the goal of developing treatments for diseases such as cancer, neurodegenerative diseases, and autoimmune disorders.

One of the most promising approaches to targeting STEAP1 is the use of small molecules, such as drugs that can inhibit the activity of STEAP1 enzymes or interact with STEAP1 to prevent it from functioning. These drugs can be administered to animals or humans, and their effectiveness can be measured using a variety of techniques, including behavioral assays, biochemical assays, and clinical trials.

Another approach to targeting STEAP1 is the use of antibodies that are designed to selectively bind to STEAP1 and prevent it from functioning. These antibodies can be used to treat diseases in which targeting STEAP1 is effective, such as cancer or neurodegenerative diseases.

While the development of drugs or antibodies that target STEAP1 is an promising approach to treating a variety of diseases, there are also concerns about the potential side effects and risks associated with these treatments. It is important for researchers to carefully study the effects of these treatments to ensure that they are safe and effective for use in humans.

Overall, STEAP1 is a protein that has significant potential as a drug target for a variety of diseases. Its role in the regulation of cell signaling pathways, inflammation, cell metabolism

Protein Name: STEAP Family Member 1

Functions: Metalloreductase that has the ability to reduce both Fe(3+) to Fe(2+) and Cu(2+) to Cu(1+). Uses NAD(+) as acceptor

The "STEAP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about STEAP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets